These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 12375042

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
    Ylisirniö S, Höyhtyä M, Mäkitaro R, Pääakkö P, Risteli J, Kinnula VL, Turpeenniemi-Hujanen T, Jukkola A.
    Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
    [Abstract] [Full Text] [Related]

  • 3. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer.
    Ylisirniö S, Sassi ML, Risteli J, Turpeenniemi-Hujanen T, Jukkola A.
    Anticancer Res; 1999 Jun; 19(6C):5577-81. PubMed ID: 10697621
    [Abstract] [Full Text] [Related]

  • 4. Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer.
    Keskikuru R, Kataja V, Kosma VM, Eskelinen M, Uusitupa M, Johansson R, Risteli L, Risteli J, Jukkola A.
    Anticancer Res; 1999 Jun; 19(5C):4481-4. PubMed ID: 10650796
    [Abstract] [Full Text] [Related]

  • 5. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer.
    Jukkola A, Bloigu R, Holli K, Joensuu H, Valavaara R, Risteli J, Blanco G.
    Anticancer Res; 2001 Jun; 21(4B):2873-6. PubMed ID: 11712779
    [Abstract] [Full Text] [Related]

  • 6. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.
    Santala M, Simojoki M, Risteli J, Risteli L, Kauppila A.
    Clin Cancer Res; 1999 Dec; 5(12):4091-6. PubMed ID: 10632345
    [Abstract] [Full Text] [Related]

  • 7. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S.
    J Am Coll Surg; 2004 Jan 01; 198(1):83-90. PubMed ID: 14698315
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, Leone A, Gazzotti F, Gagliardi S, De Cataldis A, Taffurelli M.
    Breast Cancer Res Treat; 2008 Jun 01; 109(3):405-16. PubMed ID: 17687650
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R.
    Cancer; 2006 Aug 15; 107(4):696-704. PubMed ID: 16826579
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.